Clint provides expert counsel on FDA regulatory, compliance, and enforcement issues and defends clients in healthcare and consumer protection-related investigations and enforcement proceedings, leveraging his extensive experience as a federal prosecutor at the U.S. Department of Justice (DOJ) and an associate chief counsel with the Food and Drug Administration (FDA). He joins McGuireWoods after serving nearly four years as an assistant director of the DOJ’s Consumer Protection Branch, where he managed criminal and civil enforcement of the Federal Food, Drug, and Cosmetic Act (FDCA).
In his role at the DOJ, Clint was instrumental in overseeing complex, high-profile investigations and prosecutions involving drugs, medical devices, biologics, food, dietary supplements, tobacco products, clinical research, drug supply chain integrity, counterfeiting, grant fraud, and healthcare fraud. His work ensured compliance with FDA regulations and protected public health by holding corporations and individuals accountable for violations of the FDCA and related statutes, including the False Claims Act, the Anti-Kickback statute, the Safe Doses Act, the Consumer Product Safety Act, and numerous fraud and customs laws. Clint’s deep understanding of the regulatory landscape and enforcement priorities makes him a valuable asset to clients navigating the complexities of FDA and broader healthcare industry compliance. Clint also previously served as a trial attorney at DOJ’s Consumer Protection Branch, where he led investigations and prosecutions aimed at ensuring the safety and efficacy of FDA-regulated products and combating complex consumer fraud schemes.
Before his tenure at the DOJ, Clint served in various capacities with the FDA’s Office of the Chief Counsel, where he developed a keen insight into the agency’s inner workings and regulatory processes. While with the FDA, Clint supported the agency’s Health Care Fraud and Abuse Control (HCFAC) program and worked closely with the Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, and the Office of Criminal Investigations, among other FDA components. Clint also served as a Special Assistant U.S. Attorney in multiple jurisdictions, litigating cases at both the trial and appellate levels. This dual experience at both the DOJ and FDA provides him with a unique perspective on the interplay between regulatory compliance and enforcement actions.
At McGuireWoods, Clint advises clients—including those in the pharmaceutical, biotechnology, medical device, and food industries—on a wide range of FDA-related matters. Among other things, he counsels clients on FDA inspections, warning letters, labeling and advertising issues, product recalls, clinical trial compliance, and FDA-related enforcement issues, including product seizures, injunctions, consent decrees, and civil money penalties. Clint also defends companies and individuals facing DOJ, state, and other government investigations and enforcement actions, assists clients with compliance audits and internal investigations, and helps clients establish effective corporate compliance programs.
Clint’s background as a federal enforcement official and his hands-on experience with FDA regulatory issues enable him to provide strategic, practical advice to clients facing regulatory challenges. His proactive approach helps clients anticipate and address potential issues before they escalate, ensuring compliance and minimizing risk.
-
University of Pennsylvania Carey Law SchoolJD
magna cum laude, Order of the Coif
2000 - University of California, BerkeleyBA1996
- Guest, "What Pharma Services Investors Should Know About Government Regulations, With Clint Narver," The Corner Series, November 25, 2024
- Panelist, "Life Sciences Regulatory Essentials: What Investors Should Know," 17th Annual Healthcare Finance & Growth Conference, September 25 - 26, 2024
- Presenter, "Enforcement Issues in Drug and Device Research," Health Care Compliance Association (HCCA), Research Compliance Conference, 2023
- Presenter, "Enforcement in Research," HCCA, Healthcare Enforcement Compliance Conference, 2023
- Presenter, "Clinical Trials: Deconstructing Challenges and Providing Practical Insights," Food and Drug Law Institute, 2022
- Hon. Alfred T. Goodwin, U.S. Court of Appeals for the Ninth Circuit, 2001-2002
- District of Columbia
- Author, Recent FDA Guidance Signals Future Growth for Decentralized Clinical Trials, McGuireWoods Legal Alert, October 24, 2024
- Author, Key Takeaways From the 2024 Healthcare Finance and Growth Conference, McGuireWoods Legal Alert, October 15, 2024